secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2026-05-12T10:41:58+00:00
Accession:  0001628280-26-033847
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keenova reports Q1 net sales $468M, loss $114M; reaffirms FY guidance
---------------------------------------------------------------------

- Acthar Gel net sales $170M (+47% YoY); XIAFLEX net sales $134M.
- Loss from continuing ops $114M; adjusted EBITDA $174M.
- Reaffirmed FY2026 guidance: net sales $1.94B-$2.00B, adj. EBITDA $730M-$760M.
- Realized $23M in merger synergies in Q1; on track for $100M in 2026.
- Pipeline: Phase 3 plantar fibromatosis topline expected July 2026; FDA EOP2 meeting for hammer toe June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/0001628280-26-033847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/mnk-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer